anchor instance (Q86456)

From ScienceSource
Jump to: navigation, search
No description defined
edit
Language Label Description Also known as
English
anchor instance
No description defined

    Statements

    and apoAII (by 9% and 30%, respectively with pemafibrate 0.2 mg twice daily versus 6 and 20% with
    0 references
    100 mg/day) [[56]].Table 1Summary efficacy data from published Phase II trials with pemafibrateCitation
    0 references
    471
    0 references
    1,736
    0 references
    22,408
    0 references
    16 April 2019
    0 references
    0 references
    Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. (5628452)
    0 references
     
    edit
      edit
        edit
          edit
            edit
              edit